Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 (100, 300, 800, and 1,600 mg) as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age, inclusive
Critère d'inclusion
- Refractory partial epilepsy